YMAB (Y-mAbs Therapeutics) Interest Expense : $-1.61 Mil (TTM As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Y-mAbs Therapeutics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Y-mAbs Therapeutics's interest expense for the three months ended in Dec. 2024 was $ -1.61 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2024 was $-1.61 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Y-mAbs Therapeutics's Operating Income for the three months ended in Dec. 2024 was $ -5.94 Mil. Y-mAbs Therapeutics's Interest Expense for the three months ended in Dec. 2024 was $ -1.61 Mil. Y-mAbs Therapeutics did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Y-mAbs Therapeutics Interest Expense Historical Data

The historical data trend for Y-mAbs Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Y-mAbs Therapeutics Interest Expense Chart

Y-mAbs Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Interest Expense

Get a 7-Day Free Trial

-1.85

-0.76

Y-mAbs Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Interest Expense	Get a 7-Day Free Trial															-	-	-	-	-1.61

Y-mAbs Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.61 Mil.

Y-mAbs Therapeutics (NAS:YMAB) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Y-mAbs Therapeutics's Interest Expense for the three months ended in Dec. 2024 was $-1.61 Mil. Its Operating Income for the three months ended in Dec. 2024 was $-5.94 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2024 was $0.19 Mil.

Y-mAbs Therapeutics's Interest Coverage for the quarter that ended in Dec. 2024 is calculated as

Y-mAbs Therapeutics did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Y-mAbs Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Y-mAbs Therapeutics Inc (NAS:YMAB) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

202 Carnegie Center, Suite 301, Princeton, NJ, USA, 08540

Website

https://www.ymabs.com

Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.

Executives

Michael J Rossi	director, officer: President & CEO	230 PARK AVENUE, SUITE 3350, NEW YORK NY 10169
Thomas Gad	director, officer: President and Chairman	C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169
Torben Lund-hansen	officer: Sr. VP and Head of Tech Op	C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169
Joris Wilms	officer: Sr. VP and COO	C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169
Gerard Ber	director	C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169
Bo Kruse	director, officer: EVP, CFO, Secy & Treas.	C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169
Vignesh Rajah	officer: SVP and CMO	HENRIKSHOJ 8, ROOM 4, VEDBAEK G7 DK-2950
Susan Laura Smith	officer: Senior Vice President, CCO	5 OVERLOOK CT, LAMBERTVILLE NJ 08530
Johan Wedell-wedellsborg	director, 10 percent owner	RUNGSTED STRANDVEJ 113, RUNGSTED KYST G7 2960
Biotech Aps Wg	10 percent owner	RUNGSTED STRANDVEJ 113, RUNGSTED KYST G7 2960
David N Gill	director	C/O NXSTAGE MEDICAL INC. (NXTM), 439 SOUTH UNION STREET, 5TH FLOOR, LAWRENCE MA 01843
Juan Moller San Pedro Claus	director, officer: Chief Executive Officer	C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, SUITE 3500, NEW YORK NY 10169
Laura Hamill	director	333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Mahiuddin Ahmed	officer: Sr. VP and CSO	C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, SUITE 3350, NEW YORK NY 10169
Philip Karl Herman	officer: Sr. VP and CCO	C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, SUITE 3350, NEW YORK NY 10169